Clinical Research Directory

Inclusion Criteria: * Age 18 to 70 years, inclusive, at the time of informed consent * Have a diagnosis of AQP4 antibody seropositive NMOSD according to the International Panel for NMO Diagnosis (IPND) criteria * Confirmation of NMOSD diagnosis with AQP4+ antibodies * The EDSS score should be ≤7.0 * Have clinical evidence of at least 1 documented attack or relapse (including first attack) in the last 2 years prior to screening Exclusion Criteria: * Have received rituximab or other anti-CD20 drugs treatment within 6 months * Have been used any monoclonal antibodies or research drugs for immunomodulatory effects within 3 months or within 5 half-life periods of the drug. * Females who are pregnant or lactating. * Have active infection at screening, or recent serious infection (i.e., requiring intravenous antimicrobial therapy or hospitalization) ; history of or existing infection of human immunodeficiency virus(HIV), hepatitis C virus (HCV), or Mycobacterium tuberculosis. Patients must have negative test results for HCV antibody, HIV 1 and HIV 2 antibodies, and a mycobacterium tuberculosis test (test method to be determined).